GlaxoSmithKline Pakistan (KAR:GLAXO) Other Net Income (Loss) : ₨-0 Mil (TTM As of Sep. 2024)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Other Net Income (Loss)?

GlaxoSmithKline Pakistan's Other Net Income (Loss) for the three months ended in Sep. 2024 was ₨0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was ₨-0 Mil.

GlaxoSmithKline Pakistan's quarterly Other Net Income (Loss) declined from Mar. 2024 (₨0 Mil) to Jun. 2024 (₨-0 Mil) but then increased from Jun. 2024 (₨-0 Mil) to Sep. 2024 (₨0 Mil).

GlaxoSmithKline Pakistan's annual Other Net Income (Loss) stayed the same from Dec. 2021 (₨0 Mil) to Dec. 2022 (₨0 Mil) but then declined from Dec. 2022 (₨0 Mil) to Dec. 2023 (₨-0 Mil).

GlaxoSmithKline Pakistan Other Net Income (Loss) Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Other Net Income (Loss) Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

GlaxoSmithKline Pakistan Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

GlaxoSmithKline Pakistan Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨-0 Mil.

GlaxoSmithKline Pakistan Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines